CD274 and non-small cell lung carcinoma: By analyzing harmonized patient-level data from five clinical trials involving over 200 patients with advanced NSCLC treated with PD-L1 inhibitors, the ctMoniTR initiative demonstrated that on-treatment reductions in ctDNA levels were strongly associated with improved OS and PFS (119).